Skip to main navigation
Skip to search
Skip to main content
HSC Home
Home
Research units
Profiles
Publications
Sponsored Projects
Core Facilities
Search by expertise, name or affiliation
ERG oncoprotein inhibits ANXA2 expression and function in prostate cancer
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'ERG oncoprotein inhibits ANXA2 expression and function in prostate cancer'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Biochemistry, Genetics and Molecular Biology
Actin
50%
Binding Protein
50%
Carcinogenesis
50%
CDC42
50%
Cell Function
50%
Cell Junction
50%
Cell Polarity
100%
Chromosomal Translocation
50%
Cofilin
50%
Genomics
50%
Mesenchymal-Epithelial Transition
100%
Phospholipid
50%
Promoter Region
50%
Refined Hydrothermolytic Oxidation Acid
50%
RNA
50%
Small Interfering RNA
50%
TMPRSS2
50%
Transcription Initiation Site
50%
Medicine and Dentistry
Actin Filament
25%
Biological Product
25%
Calcium Ion
25%
Carcinogenesis
25%
Cell Function
25%
Cell Junction
25%
Cell Polarity
50%
Chromosome Translocation
25%
Cofilin
25%
Epithelial Cell
50%
Immunohistochemistry
25%
Mesenchymal-Epithelial Transition
50%
Neoplasm
50%
Oncoprotein
100%
Phospholipid Binding Protein
25%
Promoter Region
25%
Prostate Cancer
100%
Prostate Cell
25%
Prostate Epithelium
25%
Small Interfering RNA
25%
Transcription Initiation Site
25%
Keyphrases
Actin Filaments
8%
Annexin A2 (ANXA2)
100%
Ca2+ Dependence
8%
Cdc42
8%
Cell Behavior
8%
Cell Formation
8%
Cell Polarity
8%
Cell-cell Junctions
8%
Chromosomal Translocation
8%
Clinical Specimens
8%
Cofilin
8%
Differentiated Cells
8%
Epithelial Phenotype
8%
Epithelial Polarity
8%
Epithelial-mesenchymal Transition
16%
Genomic Analysis
8%
Immunohistochemistry
8%
Knockdown
8%
Mechanistic Studies
8%
MRNA Level
8%
Oncoprotein
100%
Overexpression
16%
Phospholipid-binding Protein
8%
Poor Differentiation
16%
Primary Prostate Cancer
8%
Prostate Cancer
100%
Prostate Cells
8%
Prostate Epithelial Cells
8%
Prostate Epithelium
8%
Prostate Tumorigenesis
8%
Prostate-specific
8%
Protein Level
8%
Reciprocal Relationship
8%
Small Interfering RNA (siRNA)
8%
Therapeutic Targeting
8%
TMPRSS2-ERG Fusion
8%
Transcription Start Site
8%
Transcriptional Repression
16%
Tumor
16%
Well-differentiated
8%